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Therelationshipsofrenalandglomerularhypertrophiestodevelopmentofhyperﬁltrationandproteinuriaearlyinstreptozotocin-
induced diabetes were explored. Control, diabetic, phlorizin-treated controls, and diabetic male Fischer rats were used. Phlorizin
(an Na
+-glucose cotransport inhibitor) was given at a dose suﬃcient to normalize blood glucose. Inulin clearance (Cinulin)a n d
protein excretion rate (PER) were measured. For morphometry, kidney sections were stained with periodic acid Schiﬀ.A to n e
week, diabetes PER increased 2.8-folds (P<. 001), Cinulin increased 80% (P<. 01). Kidney wet and dry weights increased 10%–
12% (P<. 05), and glomerular tuft area increased 9.3% (P<. 001). Phlorizin prevented proteinuria, hyperﬁltration, and kidney
hypertrophy, but not glomerular hypertrophy. Thus, hyperﬁltration, proteinuria, and whole kidney hypertrophy were related to
hyperglycemia but not to glomerular growth. Diabetic glomerular hypertrophy constitutes an early event in the progression of
glomerular pathology which occurs in the absence of mesangial expansion and persists even after changes in protein excretion and
GFR are reversed through glycemic control.
Copyright © 2008 Slava Malatiali et al. Thisis anopen access articledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Nephropathy occurs in about 35% of patients with diabetes
mellitus and diabetic nephropathy is responsible for the
majority of kidney dialysis and transplants [1]. Renal
hyperﬁltration and hypertrophy are early manifestations of
diabetic nephropathy and much research has been devoted
to elaborate if these are major contributors to development
of overt renal disease.
Glomerular growth has been seen as the initial renal
event in diabetes and found to precede tubular growth [2].
It was believed that glomerular growth with the associated
increase in surface area for ﬁltration as observed in diabetic
animals and patients [3, 4] is a major determinant of renal
hyperﬁltration [5].
Others suggest instead that hyperﬁltration is the initial
eventandisthoughttooccurasaconsequenceofadecreased
aﬀerent arteriolar tone in hyperglycemia, probably mediated
by early glycosylation products [6]. Excess ﬁltration then
would lead to glomerular hypertension and hypertrophy
of glomerular cells in response to excessive stretch [7, 8],
resulting eventually in glomerular sclerosis [9].
Recently, it has been proposed that whole kidney growth
precedes [10] and leads to hyperﬁltration [11, 12], with a
major contribution of tubular rather than of glomerular
hypertrophy to the development of hyperﬁltration through
altered tubuloglomerular feedback. It is proposed that in
uncontrolled diabetes there is an increased tubular Na+-
glucose reabsorption [13], due to the increase in ﬁltered
glucose load and to increased expression of SGLT1, SGLT2
and GLUT2 transporters in proximal tubule cells [14]. The
decreased distal deliveryof Na+ willcausean increasein GFR
through tubuloglomerular feedback (TGF) [12, 15].
Although renal (glomerular and tubular) growth and
hyperﬁltration may contribute signiﬁcantly to development
of overt diabetic nephropathy [9], the interrelationships
between these early renal diabetic events are not clear.
Therefore, the aim of this study was to identify the
importance of glomerular and renal morphological changes
to the development of hyperﬁltration and proteinuria in
early experimental diabetes, and to study the eﬀect of
blocking tubular Na+-glucose reabsorption on glomerular
and renal hypertrophic growth and on hyperﬁltration and
proteinuria.2 Experimental Diabetes Research
2. MATERIALS AND METHODS
2.1. Animals
MaleFischerrats(8weeksold)wereplacedinaroomwithan
8:00–20:00 light, 20:00–8:00 dark cycle, kept at 22.3 ± 0.3◦C
and 31.2 ± 0.8% humidity. The rats had free access to water
and standard rat chow (801151, Special Diets Services, UK).
All animals were cared for in accordance with the Guide
for the Care and Use of Laboratory Animals and all experi-
mental protocols used in this study were approved by the
Research Administration Committee at Kuwait University.
Four groups were used: control rats (C), diabetic rats (D),
diabetic rats treated with Phlorizin (DPLZ), and control
(nondiabetic)ratstreatedwithphlorizin(CPLZ).Thisgroup
was added to study any direct renal eﬀects of phlorizin.
2.2. Inductionofdiabetes
Diabetes was induced by intraperitoneal (i.p) injection
of 55mg/kg Streptozotocin (STZ, S-0130, Sigma, USA),
dissolved in 50mM trisodium-citrate buﬀer, pH = 4.5.
Controls were given the citrate buﬀer (vehicle) alone. After
STZ injection, animals were placed in metabolic cages and
development of diabetes was conﬁrmed 16 hours later if
pronounced glucosuria and polyuria developed.
2.3. Phlorizintreatment
Diabetic (DPLZ) and control rats (CPLZ) were treated with
phlorizin (P-3449, Sigma, USA) starting 16 hours after STZ
or citratebuﬀer IP injection. Phlorizin wasdissolved atroom
temperature in propylene glycol (1,2-propanediol, 82282,
Fluka, Switzerland). The ﬁrst day the rats were given a total
of 400mg/kg phlorizin s.c. split into doses of 200mg/kg at
8:00 AM and at 8:00 PM. The second day the dose was raised
to400mg/kgtwicedailyandthetreatmentwascontinuedfor
6d a y s[ 16].
B l o o dg l u c o s el e v e l sw e r em e a s u r e dt w i c ed a i l yi nt h e
treatment group on samples taken from the tail, using a
glucometer (GLUCOTREND 2, Roche, Germany). Nonfast-
ing blood glucose levels were measured in all groups before
sacriﬁce, 7 days after treatment.
2.4. Proteinexcretionrate
Urinary protein concentration was measured using a mod-
iﬁed Lowry assay [17]. Protein excretion rate (PER) was
calculated from urinary protein concentration (Up, mg/ml)
and urine ﬂow rate (V, ml/24hrs). The urine samples
were collected over twenty four hours from rats placed in
metabolic cages.
To assess tubular proteinuria, the urinary excretion
of beta2-microglobulin was tested. The concentration of
beta2-microglobulin in rat urine was measured using
beta2-Microglobulin PET Kit (K 0052, DAKO, Denmark).
Changes in absorbance read at 340nm (Hitachi model
911, Boehringer Mannheim, Germany) were proportional
to the concentration of beta2-microglobulin in standards of
known concentrations. The urinary excretion rate of beta2-
microglobulin was calculated from its urinary concentration
and the urine ﬂow rate.
2.5. Renalhemodynamics
Glomerular ﬁltration rate was estimated by measuring the
renal plasma clearance of inulin (Cinulin). Each rat was
weighed and anaesthetized with Inactin (Thiobutabarbital
sodium C10H15N2NaO2S, T-133, Sigma, UK) at a dose
of 100mg/kg IP. The left femoral artery was catheterized
for continuous monitoring of arterial blood pressure by
a pressure transducer. Blood samples were collected from
the arterial catheter. Tracheostomy was performed to insure
proper ventilation. The femoral vein was catheterized and
an infusion with sterile Ringer’s solution (154mM NaCl,
5.61mM KCl, 2.16mM CaCl2, 5.95mM NaHCO3,5 . 5 5m M
glucose) was started at a rate of 0.06ml/min using a
syringe pump (Harvard Apparatus Ltd, UK). The bladder
was cannulated with a stainless steel cannula for urine
collection. The cannula was connected to a ﬂexible tube of
the appropriate size for urine collection. For estimation of
urine ﬂow rate, the tube was carefully removed, the urine
emptied in a tared Eppendorf tube and weighed.
After a 45–60 mininutes period of stabilization, an
infusion containing inulin (from Chicory root, I-2255,
Sigma, USA) was started. The perfusion solution contained
36mg/mL of inulin in Ringer’s, and was infused at a
rate of 0.06mL/min. Priming dose of 160mg/kg was given
intravenously. After a 30 minutes equilibration period, three
orfourtimedsamplesofurinewerecollected(15–20minutes
each). At the midpoint of each urine collection period,
an arterial blood sample of 300μlw a sc o l l e c t e di nd r y
heparinzed tubes, and centrifuged at 2000g for 10 minutes.
Plasma and urine samples were stored at −70◦C for later
analysis of inulin concentrations.
Concentration of inulin was measured in urine and
plasma samples [18] after precipitation with 10% TCA.
C l e a r a n c ev a l u e sw e r ee x p r e s s e di nm L / m i np e r1 0 0 go f
initial body weight.
2.6. Morphometry
Seven days after STZ or vehicle treatment, rats were anes-
thetized; the right kidney was removed, weighed, dried,
and reweighed. The left kidney was perfusion-ﬁxed with
10% neutral-phosphate buﬀered formalin. After 15 minutes
perfusion, the left kidney was removed and a 3mm thick
transverse cross-section was cut and placed in formalin.
Twenty four hours later sections were embedded in wax,
cut into 4 micron sections, and mounted on APES (3-
aminopropyltriethoxysilane, Sigma, A-3648) coated slides
for morphological studies. Periodic acid-Schiﬀ (PAS) stain
was used for measurements of total glomerular tuft and
mesangial matrix areas [19] .T h es e c t i o n sw e r eh y d r a t e d
and then placed in 0.5% periodic acid (5–10 minutes). The
slides were washed, successively dehydrated in 70%, 95%,
100% ethanol, and 100% xylene, protected with a cover slip
using DPX, and allowed to dry overnight. A total of 15 toSlava Malatiali et al. 3
Table 1: Body and kidney weights, blood and urinary changes in Fischer rats at one-week diabetes. Bwt0 = Initial body weight, Bwtf = ﬁnal
body weight, BG = blood glucose, V = urine ﬂow rate measured over 24 hours from rats placed in metabolic cages, PER = protein excretion
rate, Wt = weight, C = control, D = diabetic, DPLZ = phlorizin-treated diabetic, CPLZ = phlorizin-treated controls. Results are expressed as
mean ± SE and compared using unpaired two-tailed student’s t-test.
Bwt0 Bwtf BG V PER Kidney wet Kidney dry
(g) (g) (mM/l) (ml/24hrs) (mg/24hrs) wt/Bwt0% wt/Bwt0%
C 196.5 ±3.2 208 ±6.55 .6 ±0.36 .5 ±1.04 8.2 ±1.50 .39 ±0.01 0.085 ±0.003
n = 14
D 192 ±2.0 177.8 ±4.9
∗∗ 27.7 ±1.4## 63.4 ±6.4## 23.2 ±5.6# 0.43 ±0.01# 0.095 ±0.001#
n = 15
DPLZ 199.6 ±4.2 175.7 ±2.6
∗∗ 5.9 ±1.14 7 .5 ±4## 14.3 ±2.6# 0.39 ±0.02 0.078 ±0.005
n = 9
CPLZ 200 ±2.7 187.6 ±4.2
∗ϕ 5.1 ±0.22 1 .3 ±2.6##ϕϕϕ 14 ±1.8# 0.4 ±0.02 0.082 ±0.004
n = 5
∗ = P<. 05, ∗∗ = P<. 001 compared to initial weight using paired two-tailed student’s t-test. # = P<. 05, ## = P<. 001 compared to control, ϕ = P<. 05,
ϕϕϕ = P<. 001 CPLZ versus DPLZ.
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Figure 1: Blood glucose concentrations in phlorizin-treated dia-
betic rats (n = 5).
20 completely round glomeruli showing their tuft attached
at the hilum were selected randomly from all renal cortical
zones in each animal. Morphometry of glomeruli was done
with a CAS 200 cell analysis system (Becton & Dickinson
Image Cytometry Systems, USA). Total glomerular tuft area
(GA, mm2) was calculated after manual tracing of each
tuft contour. Glomerular tuft volume GTV was estimated
from
GTV = b/k ×(GA)
3/2[20],
where b = 1.38 is a shape coeﬃcient for a sphere and k = 1.1
a size distribution coeﬃcient.
Mesangial matrix area in each glomerular tuft was mea-
sured using a threshold method that selectively highlights all
PAS-positive areas within the tuft.
2.7. Statisticalanalysis
All results were expressed as mean ±SEM and were ana-
lyzed by one way ANOVA to establish diﬀerences between
groups. When F was signiﬁcant, comparisons between any
two groups were further tested using unpaired two-tailed
students t-test for equal or unequal variances according to
the equality of variance test. Correlation studies were done
using Pearson’s test. The software used was SPSS 11 for
Windows. For all statistical tests, a P value of less than 0.05
was considered signiﬁcant.
3. RESULTS
3.1. Bloodglucose,body,andkidneyweights,urine
ﬂowandproteinexcretionratesin
phlorizin-treatedanduntreateddiabeticrats
Streptozotocin-induced diabetes caused signiﬁcant increases
inbloodglucoseconcentration,urineﬂowrate,andPERand
a signiﬁcant decrease in body weight (Table 1).
Seven-day treatment of diabetic rats with phlorizin
r e d u c e dt h eb l o o dg l u c o s el e v e l st on o r m a lv a l u e s( Table 1)
within 60 hours (Figure 1); however, there was still signiﬁ-
cant diuresis and decrease in body weight (Table 1). Diuresis
and body weight loss were also observed in phlorizin-treated
control rats (Table 1).
One week of diabetes led to small (10–12%) but sig-
niﬁcant (P<. 05) increases in the kidney wet and dry
weights expressed as percentages of initial body weights
(Table 1). Phlorizin treatment prevented the mild renal
growth observed in diabetic rats. Phlorizin had no eﬀect on
renal wet or dry kidney weights in control rats.
3.2. Glomerularmorphologyandproteinuriain
phlorizin-treatedanduntreateddiabeticrats
At one-week diabetes, glomerular capillary tuft area and
volume are increased by 9.3% and 14.6%, respectively, with
no signiﬁcant change in PAS-positive mesangial matrix area
(Table 2, Figure 2). Phlorizin treatment did not prevent
glomerular growth (Figure 2, Table 2) nor altered mesangial
matrix area. However, phlorizin prevented diabetic pro-
teinuria since PER in PLZ-treated diabetic rats was not4 Experimental Diabetes Research
Table 2: Glomerular morphometry in Fischer rats at one-week diabetes: n = number of rats, N = total number of observations, GTV =
glomerular tuft volume. Tuft A = glomerular tuft area, MMA = mesangial matrix area. All variables were analyzed using one way ANOVA,
and then between group diﬀerences were compared using unpaired two-tailed student’s t-test.
Control Diabetic DPLZ
n = 5, N = 72 n = 6, N = 89 n = 5, N = 70
GTV 486 ± 11 557 ±11
∗∗∗ 621 ±153
∗∗∗
μm3 ×103
Tuft A 5293.9 ± 117.8 5796.7 ±74.4
∗∗∗ 6225.1 ±102.9
∗∗∗
μm2
MMA 163.3 ±6 159.1 ±4.5 164.6 ±6.6
μm2
MMA/tuft A%3 .07 ± 0.12 .77 ±0.12 .65 ±0.1
∗∗
∗∗ = P<. 01, ∗∗∗ = P<. 001, compared to control.
PAS
C
(a)
D
(b)
DPLZ 50μm
(c)
Figure 2: Glomerular morphological changes due to one-week diabetes in Fischer rats. Glomerular tuft area signiﬁcantly increased after
one week of diabetes. PAS positive area exhibited no change in one-week diabetics (D) when compared to controls (C). Phlorizin treatment
(DPLZ) did not prevent glomerular growth. (4μm, paraﬃn sections, periodic acid-Schiﬀ (PAS) stain, ×400).
signiﬁcantly diﬀerent from that in PLZ-treated controls.
The 1.7 fold higher PER observed in PLZ-treated control
rats compared with untreated controls is consistent with
an independent eﬀect of phlorizin on the renal handling of
proteins.
Excretion of beta2-microglobulin was measured to assess
tubular protein reabsorption [20]. There were no traces
of beta2-microglobulin in urine of control, and diabetic
rats. However, there were signiﬁcant amounts of beta2-
microglobulin in the urine of phlorizin-treated control and
diabeticrats.Urinaryexcretionsofbeta2-microglobulinwere
0.018±0.01 and0.023±0.01mg/24hin PLZ-treatedcontrols
and PLZ-treated diabetic rats, respectively (P = 0.7). Thus,
while one-week diabetes does not alter the renal handling
of beta2-microglobulin, phlorizin has an inhibitory eﬀect on
the tubular reabsorption of beta2-microglobulin in control
and diabetic rats.
The early 3-4 fold diabetes-associated increase in PER
was not found to correlate with glomerular tuft or mesangial
matrix areas or volumes, but instead was correlated with
Cinulin (Figure 3, r2 = 0.6, P<. 01), suggesting that is mostly
related to functional rather than to gross morphological
glomerular changes.
3.3. Glomerularhemodynamicchangesin
phlorizin-treatedanduntreateddiabeticrats
Mean arterial blood pressure was similar in all the groups
studied (Table 2). One-week diabetic rats had an 80%
higher (P<. 01) Cinulin than vehicle-treated nondiabetic
time controls (Table 2). Phlorizin treatment prevented the
diabetes-associated increase in Cinulin. Phlorizin had no
signiﬁcant hemodynamic eﬀect in control rats.
The eﬀects of phlorizin on diabetic-induced changes
are summarized in Figure 4. These results show that in
diabetes, phlorizin, an inhibitor of proximal tubule sodium-
glucose reabsorption, prevents glomerular hyperﬁltration,
proteinuria and whole kidney (tubular) growth but not
glomerular tuft growth.
4. DISCUSSION
One week after induction of streptozotocin diabetes,
renal and glomerular hypertrophy and hyperﬁltration were
observed in Fischer rats. Renal hypertrophy, although small,
was signiﬁcant and occurred independently of body weight
changes. Hyperﬁltration was evident by a signiﬁcant increase
in Cinulin similar to that reported earlier in SD rats [21].Slava Malatiali et al. 5
Table 3: Inulin clearances (GFR) in the experimental groups: C = control, D = diabetic, DPLZ = phlorizin-treated diabetic rats, CPLZ =
phlorizin-treated controls. Cinulin = clearance of inulin, Bwt0 = initial body weight, V = urine ﬂow rate during clearance experiment, MBP=
mean blood pressure. Clearance values were normalized to 100g of initial body weight. Results are expressed as mean ±SEM and compared
using student’s t-test.
Control (n = 7) Diabetic (n = 5) DPLZ (n = 5) CPLZ (n = 5)
Cinulin (ml·min−1·100g−1)0 .47 ±0.02 0.84 ±0.1
∗∗ 0.43 ±0.05# 0.61 ± 0.07
Bwt0 (g) 203.2 ±5.6 196.2 ±1.5 200.2 ±3.8 200 ±2.7
V (μl·min−1·100g−1)5 .6 ±0.59 .6 ±1.3
∗ 13. ±3.1
∗ 6 ±0.7
MBP (mmHg) 126.6 ±3.3 123.9 ±4.2 121.8 ±2.2 123.0 ±2.3
∗ = P<. 05, ∗∗ = P<. 01 compared to control. # = P<. 01 compared to diabetic.
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Figure 3: Correlation of protein excretion rate (PER) with inulin
clearance (P<. 001) in control, diabetic, and phlorizin-treated
control and diabetic Fischer rats. Inulin clearance was normalized
to 100g of initial body weight.
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Figure 4: Percent changes from control of kidney dry weight
to initial body weight ratio (KDW/BW0), glomerular tuft area
(GTA), protein excretion rate (PER), and glomerular ﬁltration
rate (GFR) in diabetic (D) and phlorizin-treated diabetic (DPLZ)
rats. Phlorizin treatment prevented renal growth, proteinuria and
hyperﬁltration, but did not prevent glomerular hypertrophy in
diabetic rats. Absolute values and statistics are presented in Tables
1, 2,a n d3.
One week of phlorizin treatment prevented renal whole
kidney growth and hyperﬁltration; however, it did not
prevent glomerular tuft growth. The sustained glomerular
growth with phlorizin treatment is probably related to
the fact that hyperglycemia persisted for at least 60 hours
after PLZ and STZ treatments. Hyperglycemia induces the
r e l e a s eo fg r o w t hf a c t o r ss u c ha sV E G F[ 22, 23], TGF-
β [24], and Angiotensin II [25] by resident glomerular
cells and by inﬁltrating macrophages [26] that invade the
glomeruli as early as one day after STZ treatment [26]. Once
induced,glomerulargrowthpersistsevenwhenglycemiawas
normalized with PLZ for at least three days, which indicates
thatglomerulargrowthcanpersistindependentlyoftherates
of Na+-glucose cotransport, and of hyperglycemia. Trophic
eﬀects of phlorizin per se on the glomerulus have not been
reported. Podocytes [27] and glomerular mesangial cells
[28] show SGLT 1 expression indicating that Na+-glucose
cotransportisactiveinthesecells.Blockingthispathwaywith
phlorizin will reduce glucose entry [28] and decrease their
size [29] rather than induce their growth or proliferation.
By contrast, diabetic renal tubular growth, manifested
by increases in total wet and dry kidney weights [30],
was totally prevented by phlorizin treatment. This indicates
that in STZ diabetes, hypertrophy of renal tubular cells
depends on hyperglycemia and the associated increase in
tubular Na+-glucose cotransport, and is rapidly reversed
by normalizing blood glucose concentration. Thus, diabetic
renal tubular and glomerular hypertrophies show diﬀerent
dynamicsuponnormalizationofbloodglucoseandprobably
involve diﬀerent growth pathways.
The diabetes-associated increase in GFR detected in
this study is independent of glomerular growth, since with
phlorizin treatment GFR was not elevated despite sustained
glomerular growth. Furthermore in diabetes, while the
increaseinGFRwasof80%,thatoftheglomerulartuftcross-
sectional area was only 14%. Since the ﬂow is proportional
to the square of the cross-sectional area, most of the increase
in GFR was likely due to changes in pre-or postglomerular
resistances rather than in glomerular cross-sectional area.
Similar to the ﬁndings in this study, phlorizin had no
hemodynamic eﬀects in control rats [31]. In control rats,
Na+-glucose cotransport represents at most 5% of total Na+
transport in the nephron [31]. However, in diabetic rats,
proximal Na+-dependent glucose reabsorption increases [13,
32] with increases in ﬁltered glucose load and in expression6 Experimental Diabetes Research
of glucose transporters (GLUT 2) [14, 32]. Enhanced prox-
imal reabsorption decreases distal sodium delivery leading
to preglomerular dilatation and hyperﬁltration through
tubuloglomerular feedback (TGF) [12]. Acute infusion of
phlorizin,atadosethatdoesnotnormalizethebloodglucose
level,wasshowntodecreaseGFR[13].Blockingthediabetes-
enhanced sodium glucose cotransport with PLZ decreases
expression of GLUT2 [33], greatly decreases proximal reab-
sorption of sodium, increases its distal delivery, and leads
to normalization in GFR, possibly through reversal of TGF
[12]. The eﬀect of phlorizin in preventing hyperﬁltration
in the current study was similar to that reported earlier
[13] but occurred with a higher PLZ dose which resulted in
normoglycemia and a normal ﬁltered glucose load within 60
hours of PLZ treatment. Therefore, in our experiments, the
eﬀect of phlorizin on GFR could be direct, due to inhibition
of tubular reabsorption of glucose and indirect, through
normalization of the blood glucose level and of processes
such as enhanced proximal sodium-glucose cotransport
that are dependent on hyperglycemia. The prevention of
hyperﬁltration with either low or high doses of PLZ suggests
that activation of TGF is the main mechanism by which
hyperglycemia increases GFR in diabetes and that its other
eﬀects on renal vessels have little inﬂuence on early diabetic
hyperﬁltration.
The reduction in Cinulin with PLZ cannot be accounted
for by an eﬀect of PLZ on extracellular ﬂuid volume (ECFV).
Phlorizin-treated diabetic rats had twenty-four-hour urine
ﬂow rate and diuretic response to Ringer’s infusion similar
to diabetic rats indicating similar state of hydration in
both groups. Therefore, PLZ had no signiﬁcant eﬀect on
the ECFV of these animals. Phlorizin treatment reduced
body weight in both DPLZ and CPLZ rats, but reduced
Cinulin only in DPLZ animals. Thus, the change in body
weight associated with PLZ treatment has no direct eﬀect
on Cinulin.
Hyperﬁltration was correlated with mild proteinuria in
this model of early diabetes. However, since a correlation
does not necessarily indicate a causal relationship, the
current data do not allow us to deﬁne whether diabetes
leads to mild proteinuria only through hyperﬁltration or if
additional eﬀects are involved. Early diabetic proteinuria was
totally prevented by one week phlorizin treatment indicating
that it, as well as hyperﬁltration, is due to processes
dependent on hyperglycemia and independent of glomeru-
lar tuft growth which was not reversed when glycemia
was normalized with phlorizin treatment. The absence
of excretion of beta2-microglobulin, a marker of tubular
protein transport [20], observed in diabetic rats indicates
that there is no early eﬀect of diabetes on tubular protein
reabsorption.
In this study we observed persistent glomerular hyper-
trophy in the absence of proteinuria, hyperﬁltration, or
whole kidney growth when the glycemia was controlled.
We speculate that persistent glomerular growth may be a
precursor of glomerular sclerosis and of renal insuﬃciency
(low GRF) that occur in the absence of proteinuria or of
kidney hypertrophy in about 20% of patients with diabetic
nephropathy [34–36].
5. CONCLUSION
This study shows that early in diabetes renal tubular
and glomerular hypertrophy, mild proteinuria and hyper-
ﬁltration occur in Fischer rats. The data indicate that
the renal functional changes observed early in diabetes
(hyperﬁltration and proteinuria) cannot be accounted for
by the observed glomerular hypertrophy and, in contrast to
glomerulargrowth,arereadilyreversedbyphlorizin-induced
normalization of blood glucose. Glomerular hypertrophy
is an early event in the development of STZ-diabetes-
induced glomerular pathology, occurred in the absence
of mesangial matrix expansion and persisted after short-
term normalization of the glycemia. The alleviation of early
renal functional and some structural (tubule hypertrophy)
changes in diabetes with phlorizin, as it does in the retina
[29], supports its potential therapeutic role in minimizing
diabetic microvascular disease. Further studies are needed
to investigate if diabetes-induced glomerular hypertrophy
leads to glomerulosclerosis and how it can be prevented or
reversed.
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